| Title: |
Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center Experience |
| Authors: |
Pinchera B.; Carrano R.; Salemi F.; Piccione A.; Schettino E.; Romano P.; Trucillo E.; D'Agostino A.; Sarno M.; Zappulo E.; Gentile I. |
| Contributors: |
Pinchera, B.; Carrano, R.; Salemi, F.; Piccione, A.; Schettino, E.; Romano, P.; Trucillo, E.; D'Agostino, A.; Sarno, M.; Zappulo, E.; Gentile, I. |
| Publication Year: |
2024 |
| Collection: |
IRIS Università degli Studi di Napoli Federico II |
| Subject Terms: |
COVID-19; immunosuppressed patient; kidney transplantation; Kraken variant; pre-exposure prophylaxi; SARS-CoV-2; Tixagevimab/Cilgavimab; XBB.1.5 |
| Description: |
SUMMARY Pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in immunocompromised patients has reduced the risk of breakthrough infection, disease, hospitalization, and COVID-19 related mortality. However, the advent of the Kraken variant (XBB.1.5) has limited the use of this monoclonal antibody, based on poor efficacy in in vitro studies The objective of the study was to evaluate the risk of breakthrough infection, symptomatic disease, hospitalization, intensive care admission, and COVID-19 related death in kidney transplant recipients receiving pre-exposure prophylaxis with Tixagevimab/Cilgavimab for COVID-19 in the era of the Kraken variant (XBB.1.5). In a prospective, observational study, we enrolled kidney transplant patients undergoing pre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab at the Division of Infectious Diseases of Federico II University of Naples from February 2023 to August 2023. Each patient subsequently underwent a six-month follow-up with symptom monitoring and surveillance nasopharyngeal swab for SARS-CoV-2 RNA detection every 30 days, regardless of symptoms. Thirty-four kidney transplant patients were enrolled, and in the follow-up period only one tested positive for the nasopharyngeal swab for SARSCoV-2 research with asymptomatic infection and virological recovery on the eighth day after diagnosis of infection. Therefore, no patient developed disease, no patient needed hospitalization, and no death occurred. No adverse drug reaction to Tixagevimab/Cilgavimab occurred. Our data, although derived from a limited and uncontrolled sample, show the potential of Tixagevimab/Cilgavimab as a valid and viable therapeutic strategy in pre-exposure prophylaxis for immunocompromised patients. These findings highlight the importance of conducting clinical studies on this topic. Received August 06, 2024 Accepted August 23, 2024 |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:001362614100008; volume:47; issue:3; firstpage:265; lastpage:268; numberofpages:4; journal:NEW MICROBIOLOGICA; https://hdl.handle.net/11588/991166 |
| Availability: |
https://hdl.handle.net/11588/991166 |
| Accession Number: |
edsbas.24D052C8 |
| Database: |
BASE |